(Q24247704)

https://api.crossref.org/works/10.1002%2F14651858.CD004678

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

Lipoatrophy in patients with multiple sclerosis on glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Multiple sclerosis: trial of a synthetic polypeptide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Copolymer 1: from basic research to clinical application

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Localized lipoatrophy after prolonged treatment with copolymer 1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Lack of evidence for use of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Evidence for use of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Evidence for use of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021

Extended use of glatiramer acetate (Copaxone) for MS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004678

7 January 2021